SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Capital Allocation Update

2 Nov 2023 07:00

RNS Number : 1081S
Schiehallion Fund Limited (The)
02 November 2023
 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 which forms part of domestic law in the United Kingdom pursuant to The European Union Withdrawal Act 2018, as amended by The Market Abuse (Amendment) (EU Exit) Regulations 2019.

 

The Schiehallion Fund Limited

LEI: 213800NQOLJA1JCWXQ56

 

Capital Allocation Update

 

The Board notes that, since the Conversion of the C Shares in September, the discount to net asset value ('NAV') at which the Company's Ordinary Shares trade has widened.

 

The Board and the Investment Manager are focussed on maximising returns for Shareholders over the long term and, in this context, their priority is to ensure that the Company has sufficient capital to deliver on its objectives, including supporting existing investments and satisfying the Company's ongoing working capital requirements.

 

That said, the Board and the Investment Manager believe that the Ordinary Shares represent an attractive investment opportunity at a deep discount to NAV. As such, the Company intends to allocate up to US$20m towards share repurchases given the limited available capital at this current time. The Board will keep this capital allocation and associated share buyback policy under review.

 

 

The person responsible for arranging for the release of this announcement on behalf of the Company is Mr Alex Blake of Baillie Gifford & Co Limited.

 

Enquiries

 

Winterflood Securities Limited 020 3100 0000

Neil Morgan

 

Baillie Gifford & Co 0131 275 2000

Alex Blake

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCNKDBPOBDDKDK

Related Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Back to RNS